Delving into the Latest Updates on Astellas Pharma Europe BV with Synapse

Overview

Tags

Urogenital Diseases

Other Diseases

Neoplasms

Small molecule drug

Antibody drug conjugate (ADC)

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Nervous System Diseases	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Bispecific antibody	1
Antibody drug conjugate (ADC)	1
Molecular glue	1
Monoclonal antibody	1

Top 5 Target	Count

AR(Androgen Receptor)	1
GP IIb/IIIa(Integrin alpha-IIb/beta-3)	1
CaN(Calcineurin)	1
NK3(Neurokinin 3 receptor)	1
M3 receptor(Muscarinic acetylcholine receptor M3)	1

A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF COMBINATIONS OF SOLIFENACIN SUCCINATE AND MIRABEGRON COMPARED TO SOLIFENACIN SUCCINATE AND MIRABEGRON MONOTHERAPY IN THE TREATMENT OF OVERACTIVE BLADDER”

Start Date31 Mar 2014

Sponsor / Collaborator

Astellas Pharma Europe BV

100 Clinical Results associated with Astellas Pharma Europe BV

Login to view more data

0 Patents (Medical) associated with Astellas Pharma Europe BV

Login to view more data

179

Literatures (Medical) associated with Astellas Pharma Europe BV

01 Oct 2024·Journal of Rheumatic Diseases

Corrigendum: Treatment sequence after initiating biologic therapy for patients with rheumatoid arthritis in Korea: a nationwide retrospective cohort study

Author: Lee, Sun-Kyung ; Chua, Jonathan Lumen ; Jang, Yumi ; Stoelzel, Matthias ; Kim, Soyoung ; Park, Jun Won ; Kim, Min Jung ; Shin, Kichul

[This corrects the article on p. 26 in vol. 30, PMID: 37476522.].

01 Oct 2024·Clinical Pharmacology in Drug Development

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M₃ Receptor‐Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers

Article

Author: Michon, Ingrid ; Aarden‐Bakker, Marlous ; Osaki, Fumio ; van Till, Jan Willem Olivier ; Treijtel, Nicoline ; Miyatake, Daisuke ; Sekino, Hisakuni ; Saito, Masako ; de Vries, Michiel ; Takusagawa, Shin ; Guro, Sayuri ; Kuroishi, Kentaro ; Groenendaal‐van de Meent, Dorien ; Fadini, Tomasso

AbstractASP8302 is an orally administered positive allosteric modulator of the muscarinic M3 receptor. Two Phase 1 studies were conducted, a first‐in‐human study in Europe and a Japanese phase 1 study. Both were randomized, participant‐ and investigator‐blinded, placebo‐controlled, single and multiple ascending oral doses, parallel group, clinical studies in healthy volunteers. Both studies evaluated safety and pharmacokinetics and also included salivary secretion and pupil diameter as pharmacodynamic assessments. There were no deaths, serious adverse events, or treatment‐emergent adverse events reported leading to study discontinuation. There were no clinically relevant findings in any of the laboratory, vital signs, electrocardiogram assessments, or photosensitivity testing following multiple administration of up to 150 mg or up to 140 mg once daily for 14 days in the European first‐in‐human and Japanese Phase 1 study, respectively. The pharmacokinetics of ASP8302 were approximately linear over the dose range studied. There was no evidence of drug accumulation upon repeated dosing. In both studies, ASP8302 showed a dose‐dependent pharmacodynamic effect on saliva production at doses from 100 mg onward, which was maintained during repeated dosing. No effect was observed on pupil diameter. These data supported progression of ASP8302 into Phase 2 clinical trials for further clinical development.

01 Oct 2023·Urology

Treatment Patterns in Men Prescribed Benign Prostatic Obstruction or Overactive Bladder Medications in Canada: A Retrospective Population-based Study

Article

Author: Almeida, Rodrigo Martins de ; Locke, Jennifer ; Covernton, Patrick J O ; Matta, Rano ; Herschorn, Sender ; Stoelzel, Matthias ; Neu, Sarah

OBJECTIVETo characterize first therapeutic change and healthcare resource utilization in older men initiating an overactive bladder (OAB) or benign prostatic obstruction (BPO) medication.METHODSA retrospective cohort study using health administrative data from ICES in Ontario, Canada (from April 01, 2010 to December 31, 2018) was conducted in men aged ≥66 years with ≥1 OAB (β3 agonist, antimuscarinic) or BPO (α-blocker, 5-α-reductase inhibitor) prescription and ≥1-year postindex data (index=first observed dispensation).EXCLUSIONSprescriptions for these drugs ≤1 year preindex, a related procedure ≤5 years. Patients were grouped by condition based on index prescription. Treatment changes in relation to OAB and BPO were characterized by type. Costs and healthcare resource utilization pre- and post-index were compared.RESULTSAge, geographic region, and income were similar between groups. The most common initial treatments were antimuscarinics (78.1%) in the OAB group and alpha-blockers (86.4%) in the BPO group. The OAB group was more likely to experience a therapeutic change and had a shorter time to first change in therapy (78 [30,231] vs 104 [30,350] days) and higher mean healthcare costs both pre- ($12,354 vs $11,497) and postindex ($14,423 vs $12,852). The most common first therapeutic change in both groups was discontinuing treatment (OAB: 75.6%; BPO: 69.9%).CONCLUSIONMen initiating OAB medications changed therapy sooner than those initiating BPO medications. Most discontinued first-line therapy without initiating further treatment, suggesting unmet need in this population.

100 Deals associated with Astellas Pharma Europe BV

Login to view more data

100 Translational Medicine associated with Astellas Pharma Europe BV

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

8

Approved

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Enfortumab Vedotin-ejfv ( Tubulin x nectin-4 )	Metastatic urothelial carcinoma More	Approved
Fezolinetant ( NK3 )	Vasomotor symptom More	Approved
Mirabegron ( GP IIb/IIIa )	Urinary Bladder, Overactive More	Approved
Enzalutamide ( AR )	Castration-Resistant Prostatic Cancer More	Approved
Solifenacin Succinate ( M3 receptor )	Overactive bladder syndrome More	Approved